Archive


Category: Alzheimer’s

  • Watch: Seniors Share How They’ve Made It Through the Pandemic

    Too often the voices of older people are not heard. Judith Graham, KHN’s Navigating Aging columnist, invited nine seniors from across the country to talk candidly about their highs and lows as they enter Year 3 of the pandemic, with lives reordered by risk and restriction.  How have people handled persistent stress? How have their […]

  • Inside the Tactical Tug of War Over the Controversial Alzheimer’s Drug

    The drug industry, patient advocates, and congressional Republicans have all attacked federal officials’ decision to decline routine Medicare coverage for a controversial Alzheimer’s drug. They’ve gone as far as to accuse them of tacit racism, ageism, and discrimination against the disabled — and hinted at a lawsuit — over the decision to pay only for […]

  • PhRMA submits comments urging CMS to withdraw coverage proposal

    In comments submitted this week, PhRMA urged the Centers for Medicare & Medicaid Services (CMS) to withdraw its proposed national coverage determination (NCD) for monoclonal antibodies (mAbs) for the treatment of Alzheimer’s disease. The proposed policy would set a dangerous precedent of CMS severely restricting patient access to FDA-approved medicines, putting in place barriers to […]

  • KHN’s ‘What the Health?’: Dealing With Drug Prices

    Can’t see the audio player? Click here to listen on Acast. You can also listen on Spotify, Apple Podcasts, Stitcher, Pocket Casts or wherever you listen to podcasts. Medicare officials have preliminarily decided to restrict reimbursement for Aduhelm, the controversial Alzheimer’s drug, to only patients participating in approved clinical trials. The FDA approved the drug […]

  • KHN’s ‘What the Health?’: Manchin Blows Up Biden’s ‘Build Back Better’

    Can’t see the audio player? Click here to listen on Acast. You can also listen on Spotify, Apple Podcasts, Stitcher, Pocket Casts or wherever you listen to podcasts. Sen. Joe Manchin (D-W.Va.) dashed the hopes of President Joe Biden and congressional Democrats for passage of the giant “Build Back Better” bill before the end of […]

  • Alzheimer’s Drug Targets People With Mild Cognitive Impairment. What Does That Mean?

    The approval of a controversial new drug for Alzheimer’s disease, Aduhelm, is shining a spotlight on mild cognitive impairment — problems with memory, attention, language or other cognitive tasks that exceed changes expected with normal aging. After initially indicating that Aduhelm could be prescribed to anyone with dementia, the Food and Drug Administration now specifies […]

  • KHN’s ‘What the Health?’: Here Comes Reconciliation

    Can’t see the audio player? Click here to listen on SoundCloud. You can also listen on Spotify, Apple Podcasts, Stitcher, Pocket Casts or wherever you listen to podcasts. The expansion of health benefits is a major piece of the tentative budget deal reached this week by Democrats in Congress. They plan to press ahead — […]

  • Why We May Never Know Whether the $56,000-a-Year Alzheimer’s Drug Actually Works

    The Food and Drug Administration’s approval in June of a drug purporting to slow the progression of Alzheimer’s disease was widely celebrated, but it also touched off alarms. There were worries in the scientific community about the drug’s mixed results in studies — the FDA’s own expert advisory panel was nearly unanimous in opposing its […]

  • FDA calls for investigation into its contacts with Alzheimer’s drug maker

    • Acting commissioner refers agency to inspector general • Biogen Inc’s drug Aduhelm controversially approved last month The US drug regulator has called for an independent federal investigation into the interactions between its representatives and Biogen Inc that led to the approval of the company’s Alzheimer’s disease drug last month. The drugmaker’s shares fell 3% […]

  • Doctores sopesan pros y contras de recetar la nueva droga para el Alzheimer

    Mientras médicos y expertos en políticas de salud debaten los méritos de Aduhelm, el primer fármaco para el Alzheimer aprobado en 18 años, los pacientes simplemente quieren saber: “¿me ayudará?”. Los médicos no tienen una respuesta definitiva. “En cada persona, será absolutamente imposible de predecir”, dijo el doctor Allan Levey, director del Centro de Investigación […]

  • Doctors Weigh Pros and Cons of Prescribing Hot-Button Alzheimer’s Drug

    As physicians and health policy experts debate the merits of Aduhelm, the first new drug for Alzheimer’s disease approved in 18 years, patients want to know: “Will this medication help me — and how much?” Doctors explaining the pros and cons of Aduhelm won’t have a definitive answer. “On an individual basis, it will be […]

  • Paying Billions for Controversial Alzheimer’s Drug? How About Funding This Instead?

    If you could invest $56 billion each year in improving health care for older adults, how would you spend it? On a hugely expensive medication with questionable efficacy — or something else? This isn’t an abstract question. Aduhelm, a new Alzheimer’s drug approved by the Food and Drug Administration last month, could be prescribed to […]

  • KHN’s ‘What the Health?’: Un-Trumping the ACA

    Can’t see the audio player? Click here to listen on SoundCloud. You can also listen on Spotify, Apple Podcasts, Stitcher, Pocket Casts or wherever you listen to podcasts. The Biden administration this week proposed a series of changes aimed at boosting insurance enrollment under the Affordable Care Act, undoing changes made by the Trump administration […]

  • KHN’s ‘What the Health?’: The ACA Lives

    Can’t see the audio player? Click here to listen on SoundCloud. You can also listen on Spotify, Apple Podcasts, Stitcher, Pocket Casts or wherever you listen to podcasts. For the third time in nine years, the Affordable Care Act has survived a constitutional challenge at the Supreme Court. In a 7-2 decision, the court ruled […]

  • How research evolves and brings new hope to patients

    Before medicines can be made available to patients, they often begin as ideas that are based on newly discovered molecules and cells, strange phenomena or little-understood processes in the body. The biopharmaceutical industry’s unique role in the research ecosystem is to utilize its scientific, medical and industrial expertise to take the necessary risks to build […]

  • KHN’s ‘What the Health?’: Our 200th Episode!

    Can’t see the audio player? Click here to listen on SoundCloud. You can also listen on Spotify, Apple Podcasts, Stitcher, Pocket Casts or wherever you listen to podcasts. The Food and Drug Administration found itself in the hot seat this week when it approved a controversial new drug to treat Alzheimer’s disease with scant evidence […]

  • Double resignation over Aduhelm approval depletes FDA’s CNS adcomm

    Two members of an FDA advisory committee have now resigned in protest over Monday’s approval of Biogen’s Alzheimer’s disease drug Aduhelm despite an overwhelming vote against doing so. Washington University neurologist Joel Perlmutter was the first to announce he was stepping down from the Peripheral and Central Nervous System Drugs Advisory Committee on the day […]

  • FDA Weighs Approval of a Lucrative Alzheimer’s Drug but Benefits Are Iffy

    The Food and Drug Administration’s decision next week whether to approve the first treatment for Alzheimer’s disease highlights a deep division over the drug’s benefits as well as criticism about the integrity of the FDA approval process. This story also ran on The Daily Beast. It can be republished for free. The agency said it […]

  • Biogen’s eye disease gene therapy fails ahead of FDA Alzheimer’s ruling

    Biogen has downbeat news about its gene therapy for the rare inherited eye disease, X-linked retinitis pigmentosa, announcing the shot failed to meet its target in a phase 2/3 study. A final FDA decision on Biogen’s controversial Alzheimer’s drug aducanumab is due before the beginning of next month and the company needs some positive pipeline […]

  • Health Innovators: Teresa Arroyo-Gallego, nQ Medical

    In this episode of our Health Innovators series, Paul Tunnah is joined by Teresa Arroyo-Gallego, chief data scientist at artificial intelligence technology company nQ Medical. As a researcher in the biomedical engineering lab of the Massachusetts Institute of Technology (MIT), Teresa leads a team developing the neuroQWERTY technology to detect early signs of motor decline in […]

  • Trouble Managing Money May Be an Early Sign of Dementia

    After Maria Turner’s minivan was totaled in an accident a dozen years ago, she grew impatient waiting for the insurance company to process the claim. One night, she saw a red pickup truck on eBay for $20,000. She thought it was just what she needed. She clicked “buy it now” and went to bed. The […]

  • Can your typing patterns reveal if you have Alzheimer’s?

    The neuroQWERTY technology can analyse people’s typing for signs of motor conditions like Parkinson’s disease – and now the team behind it is looking to expand into the notoriously-difficult area of dementia. Teresa Arroyo-Gallego tells us about the science behind the technology and how the team hopes to reshape cognitive screening.  While many disease areas […]

  • 2nd Gene Therapy for Neurological Disorders Europe

    Returning digitally in 2021, the 2nd Annual Gene Therapy for Neurological Disorders Europe meeting will possibly be your last chance to attend a European meeting without the airmiles! Focusing on the industry’s challenges of developing and delivering gene therapies to the CNS and bringing fresh faces and emerging companies into the conversation, this is not one to miss […]

  • FDA grew too close to Biogen during Alzheimer’s drug development, doctors say

    The FDA got too close to Biogen during the development of the Alzheimer’s drug aducanumab, according to its own expert advisers who are urging the regulator to reject it in the coming weeks. With the deadline for a regulatory decision approaching for aducanumab in June, three doctors who took part in the expert advisory board […]

  • Biogen shares soar as FDA delays decision on aducanumab

    The FDA has delayed its decision on aducanumab, the troubled Alzheimer’s drug from Biogen and Eisai by three months, raising hopes that it could be approved after all. Biogen’s share price jumped considerably after the news broke at the back end of last week, as an FDA rejection had been on the cards after an […]

  • If I Have Cancer, Dementia or MS, Should I Get the Covid Vaccine?

    As public demand grows for limited supplies of covid-19 vaccines, questions remain about the vaccines’ appropriateness for older adults with various illnesses. Among them are cancer patients receiving active treatment, dementia patients near the end of their lives and people with autoimmune conditions. Recently, a number of readers have asked me whether older relatives with […]

  • Readers and Tweeters Fight Stigma and Salute Front-Line Workers

    Letters to the Editor is a periodic feature. We welcome all comments and will publish a selection. We edit for length and clarity and require full names. In case you need your blood to boil, read this story about a woman’s surprise medical bill for lab tests she never requested and was never informed would happen. #health #healthcare […]

  • 9th Annual Neurodegenerative Drug Development Summit

    The 9th Neurodegenerative Drug Development Summit is the industry’s definitive and unrivalled forum focused on revealing hot and promising pockets of innovation in drug discovery for neurodegenerative diseases and combating translational challenges by shining a light on pioneering companies leading the way to meet this dire medical need. Building on the success of last year’s meeting, this […]

  • Eisai forges CNS alliance with UK’s Wren Therapeutics

    Japanese drugmaker Eisai has teamed up with UK biotech Wren Therapeutics on an R&D programme seeking drugs for neurodegenerative disorders. The two companies will focus their efforts on alpha-synuclein, a pathway that has been implicated in disorders such as dementia with Lewy bodies (DLB) and Parkinson’s disease (PD). DLB and PD are both so-called synucleinopathies, […]

  • China’s Green Valley prepares US trial of Alzheimer’s drug inspired by algae

    As an influential panel of FDA-appointed experts prepares its verdict on Biogen’s Alzheimer’s drug, a little known China-based pharma is hoping to succeed where big name rivals have failed and develop a drug that is effective against the disease. For almost two decades there has been no progress with new therapies for Alzheimers – the […]

  • Guest Post: Honoring Hispanic Heritage Month by taking action on health equity

    Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. Today, we are pleased to welcome a guest post from Jason Resendez who is the executive director of the UsAgainstAlzheimer’s Center for Brain Health Equity and head of the LatinosAgainstAlzheimer’s Coalition, […]

  • Biogen’s shares surge again as FDA hurries Alzheimer’s drug review

    Biogen’s Alzheimer’s drug aducanumab could be on the market in the next few months after the FDA accepted a clinical trial dossier and granted a fast Priority Review. The FDA reserves these quick reviews for drugs that have the potential to improve care standards for serious diseases. There have been no new drugs approved for […]